SARS-CoV-2 variants and COVID-19 vaccines: Current challenges and future strategies

References

• Doroftei B, Ciobica A, Ilie OD, et al. Mini review discussing the reliability and efficiency of COVID 19 vaccines. Diagnostics (Basel, Switzerland). 2021;11(4):579.
   PubMedGoogle Scholar
• Jia Z, Gong W. Will mutations in the spike protein of SARS CoV2 lead to the failure of COVID 19 vaccines? J Korean Med Sci. 2021;36(18):e124. doi:10.3346/jkms.2021.36.e124.
   PubMed Web of Science ®Google Scholar
• Gong W, Aspatwar A, Wang S, et al. COVID 19 pandemic: SARS CoV 2 specific vaccines and challenges, protection via BCG trained immunity, and clinical trials. Expert Rev Vaccines 2021;20(7):857–880. doi:10.1080/14760584.2021.1938550.
   PubMed Web of Science ®Google Scholar
• Aspatwar A, Gong W, Wang S, et al. Tuberculosis vaccine BCG: the magical effect of the old vaccine in the fight against the COVID 19 pandemic. Int Rev Immunol. 2021;41(2):283–296.
   PubMed Web of Science ®Google Scholar
• Galloway SE, Paul P, MacCannell DR, et al. Emergence of SARS CoV 2 B.1.1.7 lineage United States, December 29, 2020 January 12, 2021. MMWR Morb Mortal Wkly Rep. 2021;70(3):95–99. doi:10.15585/mmwr.mm7003e2.
   PubMed Web of Science ®Google Scholar
• Tegally H, Wilkinson E, Giovanetti M, et al. Emergence and rapid spread of a new severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) lineage with multiple spike mutations in South Africa. medRxiv: the preprint server for health sciences. 2020.
   Google Scholar
• Wei Lin L, Xiaoqiong G, Federica A, et al. Quantitative SARS-CoV-2 tracking of variants Delta, Delta plus, Kappa and Beta in wastewater by allele-specific RT-qPCR. medRxiv: the preprint server for health sciences. 2021.
   Google Scholar
• Qin S, Cui M, Sun S, et al. Genome characterization and potential risk assessment of the novel SARS-CoV-2 variant omicron (B.1.1.529). Zoonoses. 2021;1(1). doi:10.15212/ZOONOSES-2021-0024.
   Google Scholar
• Cherian S, Potdar V, Jadhav S, et al. SARS-CoV-2 spike mutations, L452R, T478K, E484Q and P681R, in the second wave of COVID-19 in Maharashtra, India. Microorganisms. 2021;9(7):1542. doi:10.3390/microorganisms9071542.
   PubMed Web of Science ®Google Scholar
• Davies NG, Abbott S, Barnard RC, et al. Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England. Science (New York, NY). 2021;372(6538):372. doi:10.1126/science.abg3055.
   Google Scholar
• Lin L, Liu Y, Tang X, et al. The disease severity and clinical outcomes of the SARS-CoV-2 variants of concern. Front Public Health. 2021;9:775224. doi:10.3389/fpubh.2021.775224.
   PubMed Web of Science ®Google Scholar
• Patone M, Thomas K, Hatch R, et al. Mortality and critical care unit admission associated with the SARS-CoV-2 lineage B.1.1.7 in England: an observational cohort study. Lancet Infect Dis. 2021;21(11):1518–1528. doi:10.1016/S1473-3099(21)00318-2.
   PubMed Web of Science ®Google Scholar
• FDA. Fact sheet for health care providers emergency use authorization (EUA) of bamlanivimab and etesevimab. Indianapolis, USA; 2021.
   Google Scholar
• Wang P, Nair MS, Liu L, et al. Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7. Nature. 2021;593(7857):130–135. doi:10.1038/s41586-021-03398-2.
   PubMed Web of Science ®Google Scholar
• Heath PT, Galiza EP, Baxter DN, et al. Safety and efficacy of NVX-CoV2373 Covid-19 vaccine. N Engl J Med. 2021;385(13):1172–1183. doi:10.1056/NEJMoa2107659.
   PubMed Web of Science ®Google Scholar
• Lopez Bernal J, Andrews N, Gower C, et al. Effectiveness of Covid-19 vaccines against the B.1.617.2 (Delta) variant. N Engl J Med. 2021;385(7):585–594. doi:10.1056/NEJMoa2108891.
   PubMed Web of Science ®Google Scholar
• Zani A, Caccuri F, Messali S, et al. Serosurvey in BNT162b2 vaccine-elicited neutralizing antibodies against authentic B.1, B.1.1.7, B.1.351, B.1.525 and P.1 SARS-CoV-2 variants. Emerg Microbes Infect. 2021;10(1):1241–1243. doi:10.1080/22221751.2021.1940305.
   PubMed Web of Science ®Google Scholar
• Shen X, Tang H, McDanal C, et al. SARS-CoV-2 variant B.1.1.7 is susceptible to neutralizing antibodies elicited by ancestral spike vaccines. Cell Host Microbe. 2021;29(4):529–539.e3. doi:10.1016/j.chom.2021.03.002.
   PubMed Web of Science ®Google Scholar
• Pearson CA, Russell TW, Davie NG, et al. Estimates of severity and transmissibility of novel South Africa SARS-CoV-2 variant 501Y.V2. 2021.
   Google Scholar
• FDA. Fact Sheet for Health Care Providers Emergency Use Authorization (EUA) of Regen-Covtm (Casirivimab and Imdevimab). New York, USA: U.S. Food and Drug Administration (FDA); 2021:57.
   Google Scholar
• Wu K, Werner AP, Moliva JI, et al. mRNA-1273 vaccine induces neutralizing antibodies against spike mutants from global SARS-CoV-2 variants. bioRxiv: the preprint server for biology. 2021.
   Google Scholar
• Madhi SA, Baillie V, Cutland CL, et al. Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant. N Engl J Med. 2021;384(20):1885–1898. doi:10.1056/NEJMoa2102214.
   PubMed Web of Science ®Google Scholar
• Wang P, Casner RG, Nair MS, et al. Increased resistance of SARS-CoV-2 variant P.1 to antibody neutralization. Cell Host Microbe. 2021;29(5):747–751.e4. doi:10.1016/j.chom.2021.04.007.
   PubMed Web of Science ®Google Scholar
• Dougherty K, Mannell M, Naqvi O, et al. SARS-CoV-2 B.1.617.2 (Delta) variant COVID-19 outbreak associated with a gymnastics facility - Oklahoma, April–May 2021. MMWR Morb Mortal Wkly Rep. 2021;70(28):1004–1007. doi:10.15585/mmwr.mm7028e2.
   PubMed Web of Science ®Google Scholar
• Wall EC, Wu M, Harvey R, et al. Neutralising antibody activity against SARS-CoV-2 VOCs B.1.617.2 and B.1.351 by BNT162b2 vaccination. Lancet (London, England). 2021;397(10292):2331–2333. doi:10.1016/S0140-6736(21)01290-3.
   PubMed Web of Science ®Google Scholar
• Iacobucci G. Covid-19: local councils initiate surge vaccination to tackle B.1.617.2 variant. BMJ. 2021;373:n1361. doi:10.1136/bmj.n1361.
   PubMedGoogle Scholar
• Mahase E. Covid-19: hospital admission 50–70% less likely with omicron than delta, but transmission a major concern. BMJ. 2021;375:n3151. doi:10.1136/bmj.n3151.
   PubMed Web of Science ®Google Scholar
• Vogel G, Kupferschmidt K. Early lab studies shed light on Omicron’s behavior. Science. 2021;374(6575):1543–1544. doi:10.1126/science.acz9878.
   PubMed Web of Science ®Google Scholar
• Cele S, Jackson L, Khan K, et al. SARS-CoV-2 Omicron has extensive but incomplete escape of Pfizer BNT162b2 elicited neutralization and requires ACE2 for infection. medRxiv: the preprint server for health sciences. 2021.
   Google Scholar
• Pulliam JRC, van Schalkwyk C, Govender N, et al. Increased risk of SARS-CoV-2 reinfection associated with emergence of the Omicron variant in South Africa. medRxiv: the preprint server for health sciences. 2021.
   Google Scholar
• Xie X, Han JB, Ma G, et al. Emerging SARS-CoV-2 B.1.621/Mu variant is prominently resistant to inactivated vaccine-elicited antibodies. Zool Res. 2021;42(6):789–791. doi:10.24272/j.issn.2095-8137.2021.343.
   PubMed Web of Science ®Google Scholar
• Katia B, Lina SS, Lei Q, et al. Effectiveness of mRNA-1273 against Delta, Mu, and other emerging variants. medRxiv: the preprint server for health sciences. 2021.
   Google Scholar
• Mehul S, Prabhu SA, Mengyun H, et al. Durability of immune responses to the BNT162b2 mRNA vaccine. bioRxiv: the preprint server for biology. 2021.
   Google Scholar
• Kei M, Sundararaj SJ, Hideaki K, et al. Neutralizing efficacy of vaccines against the SARS-CoV-2 Mu variant. medRxiv: the preprint server for health sciences. 2021.
   Google Scholar
• Tada T, Zhou H, Dcosta BM, et al. SARS-CoV-2 Lambda variant remains susceptible to neutralization by mRNA vaccine-elicited antibodies and convalescent serum. bioRxiv: the preprint server for biology. 2021.
   Google Scholar
• Acevedo ML, Alonso-Palomares L, Bustamante A, et al. Infectivity and immune escape of the new SARS-CoV-2 variant of interest Lambda. medRxiv: the preprint server for health sciences. 2021.
   Google Scholar
• Wood DA, Aleem A, Davis D. Providing Access to Monoclonal Antibody Treatment of Coronavirus (COVID-19) Patients in Rural and Underserved Areas. Treasure Island (FL): StatPearls Publishing; 2021.
   Google Scholar
• WHO. Classification of omicron (B.1.1.529): SARS-CoV-2 variant of concern. 2021.
   Google Scholar
• Torjesen I. Covid-19: omicron may be more transmissible than other variants and partly resistant to existing vaccines, scientists fear. BMJ. 2021;375:n2943. doi:10.1136/bmj.n2943.
   PubMed Web of Science ®Google Scholar
• Walls AC, Park YJ, Tortorici MA, et al. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell. 2020;181(2):281–292.e6. doi:10.1016/j.cell.2020.02.058.
   PubMed Web of Science ®Google Scholar
• Zhang L, Mann M, Syed ZA, et al. Furin cleavage of the SARS-CoV-2 spike is modulated by O-glycosylation. Proc Natl Acad Sci U S A. 2021;118(47):e2109905118.
   PubMed Web of Science ®Google Scholar
• Tchesnokova V, Kulasekara H, Larson L, et al. Acquisition of the L452R mutation in the ACE2-binding interface of Spike protein triggers recent massive expansion of SARS-CoV-2 variants. J Clin Microbiol. 2021;59(11):e0092121. doi:10.1128/JCM.00921-21.
   PubMed Web of Science ®Google Scholar
• COVID-19 Vaccines. Drugs and Lactation Database (LactMed). Bethesda (MD): National Library of Medicine (US); 2006.
   Google Scholar
• Shinde V, Bhikha S, Hoosain Z, et al. Efficacy of NVX-CoV2373 Covid-19 vaccine against the B.1.351 variant. N Engl J Med. 2021;384(20):1899–1909. doi:10.1056/NEJMoa2103055.
   PubMed Web of Science ®Google Scholar
• Huang B, Dai L, Wang H, et al. Neutralization of SARS-CoV-2 VOC 501Y.V2 by human antisera elicited by both inactivated BBIBP-CorV and recombinant dimeric RBD ZF2001 vaccines. bioRxiv: the preprint server for biology. 2021.
   Google Scholar
• Zhao X, Zheng A, Li D, et al. Neutralization of recombinant RBD-subunit vaccine ZF2001-elicited antisera to SARS-CoV-2 variants including Delta. bioRxiv: the preprint server for biology. 2021.
   Google Scholar
• Jangra S, Ye C, Rathnasinghe R, et al. SARS-CoV-2 spike E484K mutation reduces antibody neutralisation. Lancet Microbe. 2021;2(7):e283–e4. doi:10.1016/S2666-5247(21)00068-9.
   PubMedGoogle Scholar
• Deng X, Garcia-Knight MA, Khalid MM, et al. Transmission, infectivity, and antibody neutralization of an emerging SARS-CoV-2 variant in California carrying a L452R spike protein mutation. medRxiv: the preprint server for health sciences. 2021.
   Google Scholar
• Li Q, Wu J, Nie J, et al. The impact of mutations in SARS-CoV-2 spike on viral infectivity and antigenicity. Cell. 2020;182(5):1284–1294 e9. doi:10.1016/j.cell.2020.07.012.
   PubMed Web of Science ®Google Scholar
• Farinholt T, Doddapaneni H, Qin X, et al. Transmission event of SARS-CoV-2 Delta variant reveals multiple vaccine breakthrough infections. medRxiv: the preprint server for health sciences. 2021.
   Google Scholar
• Gong W, Wu X. Is the tuberculosis vaccine BCG an alternative weapon for developing countries to defeat COVID-19? Indian J Tuberc. 2021;68(3):401–404. doi:10.1016/j.ijtb.2020.10.012.
   PubMedGoogle Scholar
• Qi S, XiaoPing D. Rapid global spread of the SARS-CoV-2 delta (B.1.617.2) variant: spatiotemporal variation and public health impact. Zoonoses. 2021;1.
   Google Scholar
• Emary KRW, Golubchik T, Aley PK, et al. Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial. Lancet. 2021;397(10282):1351–1362. doi:10.1016/S0140-6736(21)00628-0.
   PubMed Web of Science ®Google Scholar
• Sadoff J, Gray G, Vandebosch A, et al. Safety and efficacy of single-dose Ad26.COV2.S vaccine against Covid-19. N Engl J Med. 2021;384(23):2187–2201. doi:10.1056/NEJMoa2101544.
   PubMed Web of Science ®Google Scholar
• Thomas SJ, Moreira ED, Kitchin N, et al. Six month safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine. medRxiv: the preprint server for health sciences. 2021.
   Google Scholar
• Ella R, Reddy S, Blackwelder W, et al. Efficacy, safety, and lot to lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): a, double-blind, randomised, controlled phase 3 trial. medRxiv: the preprint server for health sciences. 2021.
   Google Scholar
• Novavax. Novavax COVID-19 vaccine demonstrates 89.3% efficacy in UK phase 3 trial. Novavax; 2021. https://ir.novavax.com/news-releases/news-release-details/novavax-covid-19-vaccine-demonstrates-893-efficacy-uk-phase-3.
   Google Scholar
• Baden LR, El Sahly HM, Essink B, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021;384(5):403–416. doi:10.1056/NEJMoa2035389.
   PubMed Web of Science ®Google Scholar
• Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020;383(27):2603–2615. doi:10.1056/NEJMoa2034577.
   PubMed Web of Science ®Google Scholar
• Voysey M, Clemens SAC, Madhi SA, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet (London, England). 2021;397(10269):99–111. doi:10.1016/S0140-6736(20)32661-1.
   PubMed Web of Science ®Google Scholar
• Voysey M, Costa Clemens SA, Madhi SA, et al. Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. Lancet (London, England). 2021;397(10277):881–891. doi:10.1016/S0140-6736(21)00432-3.
   PubMed Web of Science ®Google Scholar
• Stephenson KE, Le Gars M, Sadoff J, et al. Immunogenicity of the Ad26.COV2.S Vaccine for COVID-19. JAMA. 2021;325(15):1535–1544. doi:10.1001/jama.2021.3645.
   PubMed Web of Science ®Google Scholar
• Tian JH, Patel N, Haupt R, et al. SARS-CoV-2 spike glycoprotein vaccine candidate NVX-CoV2373 immunogenicity in baboons and protection in mice. Nat Commun. 2021;12(1):372. doi:10.1038/s41467-020-20653-8.
   PubMed Web of Science ®Google Scholar
• Guebre-Xabier M, Patel N, Tian JH, et al. NVX-CoV2373 vaccine protects cynomolgus macaque upper and lower airways against SARS-CoV-2 challenge. Vaccine. 2020;38(50):7892–7896. doi:10.1016/j.vaccine.2020.10.064.
   PubMed Web of Science ®Google Scholar
• Mukhopadhyay L, Yadav PD, Gupta N, et al. Comparison of the immunogenicity & protective efficacy of various SARS-CoV-2 vaccine candidates in non-human primates. Indian J Med Res. 2021;153(1 & 2):93–114. doi:10.4103/ijmr.IJMR_4431_20.
   PubMed Web of Science ®Google Scholar
• Keech C, Albert G, Cho I, et al. Phase 1-2 trial of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine. N Engl J Med. 2020;383(24):2320–2332. doi:10.1056/NEJMoa2026920.
   PubMed Web of Science ®Google Scholar
• Frenck RW, Jr, Klein NP, Kitchin N, et al. Safety, immunogenicity, and efficacy of the BNT162b2 Covid-19 vaccine in adolescents. N Engl J Med. 2021;385(3):239–250. doi:10.1056/NEJMoa2107456.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Tracking SARS-CoV-2 variants. https://wwwwhoint/en/activities/tracking-SARS-CoV-2-variants/. 2021.
   Google Scholar
• Collier DA, De Marco A, Ferreira I, et al. Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies. Nature. 2021;593(7857):136–141. doi:10.1038/s41586-021-03412-7.
   PubMed Web of Science ®Google Scholar
• Giles B, Meredith P, Robson S, et al. The SARS-CoV-2 B.1.1.7 variant and increased clinical severity-the jury is out. Lancet Infect Dis. 2021;21(9):1213–1214. doi:10.1016/S1473-3099(21)00356-X.
   PubMed Web of Science ®Google Scholar
• Khan A, Zia T, Suleman M, et al. Higher infectivity of the SARS-CoV-2 new variants is associated with K417N/T, E484K, and N501Y mutants: an insight from structural data. J Cell Physiol. 2021;236(10):7045–7057. doi:10.1002/jcp.30367.
   PubMed Web of Science ®Google Scholar
• Funk T, Pharris A, Spiteri G, et al. Characteristics of SARS-CoV-2 variants of concern B.1.1.7, B.1.351 or P.1: data from seven EU/EEA countries, weeks 38/2020 to 10/2021. Euro surveillance: bulletin. Europeen sur les maladies transmissibles = European Communicable Disease Bulletin. 2021;(16):2100348.
   Google Scholar
• Ramanathan M, Ferguson ID, Miao W, et al. SARS-CoV-2 B.1.1.7 and B.1.351 Spike variants bind human ACE2 with increased affinity. bioRxiv: the preprint server for biology. 2021.
   Google Scholar
• Mahase E. Covid-19: Novavax vaccine efficacy is 86% against UK variant and 60% against South African variant. BMJ. 2021;372:n296. doi:10.1136/bmj.n296.
   PubMed Web of Science ®Google Scholar
• Sabino EC, Buss LF, Carvalho MPS, et al. Resurgence of COVID-19 in Manaus, Brazil, despite high seroprevalence. Lancet (London, England). 2021;397(10273):452–455. doi:10.1016/S0140-6736(21)00183-5.
   PubMed Web of Science ®Google Scholar
• Charmet T, Schaeffer L, Grant R, et al. Impact of original, B.1.1.7, and B.1.351/P.1 SARS-CoV-2 lineages on vaccine effectiveness of two doses of COVID-19 mRNA vaccines: results from a nationwide case-control study in France. Lancet Reg Health Eur. 2021;8:100171. doi:10.1016/j.lanepe.2021.100171.
   PubMedGoogle Scholar
• Deng X, Garcia-Knight MA, Khalid MM, et al. Transmission, infectivity, and neutralization of a spike L452R SARS-CoV-2 variant. Cell. 2021;184(13):3426–3437.e8. doi:10.1016/j.cell.2021.04.025.
   PubMed Web of Science ®Google Scholar
• World Health Organization. SARS-CoV-2 Delta variant now dominant in much of European region; efforts must be reinforced to prevent transmission, warns WHO Regional Office for Europe and ECDC. https://wwweurowhoint/en/media-centre/sections/press-releases/2021/sars-cov-2-delta-variant-now-dominant-in-much-of-european-region-efforts-must-be-reinforced-to-prevent-transmission,-warns-who-regional-office-for-europe-and-ecdc. 2021.
   Google Scholar
• American S. Why do variants such as delta become dominant? https://wwwscientificamericancom/article/why-do-variants-such-as-delta-become-dominant1/. 2021.
   Google Scholar
• Chen J, Wang R, Wang M, et al. Mutations strengthened SARS-CoV-2 infectivity. J Mol Biol. 2020;432(19):5212–5226. doi:10.1016/j.jmb.2020.07.009.
   PubMed Web of Science ®Google Scholar
• Mlcochova P, Kemp SA, Dhar MS, et al. SARS-CoV-2 B.1.617.2 Delta variant replication and immune evasion. Nature. 2021;599(7883):114–119. doi:10.1038/s41586-021-03944-y.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Classification of omicron (B.1.1.529): SARS-CoV-2 variant of concern. https://wwwwhoint/news/item/26-11-2021-classification-of-omicron-(b11529)-sars-cov-2-variant-of-concern. 2021.
   Google Scholar
• Harrington D, Kele B, Pereira S, et al. Confirmed reinfection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant VOC-202012/01. Clin Infect Dis. 2021;73(10):1946–1947. doi:10.1093/cid/ciab014.
   PubMed Web of Science ®Google Scholar
• Coutinho RM, Marquitti FMD, Ferreira LS, et al. Model-based estimation of transmissibility and reinfection of SARS-CoV-2 P.1 variant. Commun Med (Lond). 2021;1:48. doi:10.1038/s43856-021-00048-6.
   PubMedGoogle Scholar
• Shastri J, Parikh S, Aggarwal V, et al. Severe SARS-CoV-2 breakthrough reinfection with delta variant after recovery from breakthrough infection by alpha variant in a fully vaccinated health worker. Front Med (Lausanne). 2021;8:737007. doi:10.3389/fmed.2021.737007.
   PubMed Web of Science ®Google Scholar
• Kreier F. ‘Unprecedented achievement’: who received the first billion COVID vaccinations? Nature. 2021. doi:10.1038/d41586-021-01136-2.
   Google Scholar
• Li Q, Lu H. Latest updates on COVID-19 vaccines. Biosci Trends. 2021;14(6):463–466. doi:10.5582/bst.2020.03445.
   PubMed Web of Science ®Google Scholar
• Cantón R, De Lucas Ramos P, García-Botella A, et al. New variants of SARS-CoV-2. Rev Esp Quimioter. 2021;34(5):419–428. doi:10.37201/req/071.2021.
   PubMed Web of Science ®Google Scholar
• Eaton L. Covid-19: WHO warns against "vaccine nationalism" or face further virus mutations. BMJ. 2021;372:n292. doi:10.1136/bmj.n292.
   PubMedGoogle Scholar
• Wouters OJ, Shadlen KC, Salcher-Konrad M, et al. Challenges in ensuring global access to COVID-19 vaccines: production, affordability, allocation, and deployment. Lancet (London, England). 2021;397(10278):1023–1034. doi:10.1016/S0140-6736(21)00306-8.
   PubMed Web of Science ®Google Scholar
• Mills MC, Salisbury D. The challenges of distributing COVID-19 vaccinations. EClinicalMedicine. 2021;31:100674. doi:10.1016/j.eclinm.2020.100674.
   PubMedGoogle Scholar
• Yang J-R, Kuo C-Y, Huang H-Y, et al. Newly emerging mutations in the matrix genes of the human influenza A(H1N1)pdm09 and A(H3N2) viruses reduce the detection sensitivity of real-time reverse transcription-PCR. J Clin Microbiol. 2014;52(1):76–82. doi:10.1128/JCM.02467-13.
   PubMed Web of Science ®Google Scholar
• Jindal H, Jain S, Suvvari TK, et al. False-negative RT-PCR findings and double mutant variant as factors of an overwhelming second wave of COVID-19 in India: an emerging global health disaster. SN Compr Clin Med. 2021;3(12):2383–2388. doi:10.1007/s42399-021-01059-z.
   PubMedGoogle Scholar
• Ascoli CA. Could mutations of SARS-CoV-2 suppress diagnostic detection? Nat Biotechnol. 2021;39(3):274–275. doi:10.1038/s41587-021-00845-3.
   PubMed Web of Science ®Google Scholar
• MacDonald NE, SAGE Working Group on Vaccine Hesitancy. Vaccine hesitancy: definition, scope and determinants. Vaccine. 2015;33(34):4161–4164. doi:10.1016/j.vaccine.2015.04.036.
   PubMed Web of Science ®Google Scholar
• Machingaidze S, Wiysonge CS. Understanding COVID-19 vaccine hesitancy. Nat Med. 2021;27(8):1338–1339. doi:10.1038/s41591-021-01459-7.
   PubMed Web of Science ®Google Scholar
• Callaway E. Fast-spreading COVID variant can elude immune responses. Nature. 2021;589(7843):500–501. doi:10.1038/d41586-021-00121-z.
   PubMed Web of Science ®Google Scholar
• Dan JM, Mateus J, Kato Y, et al. Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection. Science (New York, NY). 2021;371(6529):371. doi:10.1126/science.abf4063.
   Google Scholar
• Wajnberg A, Amanat F, Firpo A, et al. Robust neutralizing antibodies to SARS-CoV-2 infection persist for months. Science. 2020;370(6521):1227–1230. doi:10.1126/science.abd7728.
   PubMed Web of Science ®Google Scholar
• Pilz S, Chakeri A, Ioannidis JP, et al. SARS-CoV-2 re-infection risk in Austria. Eur J Clin Invest. 2021;51(4):e13520. doi:10.1111/eci.13520.
   PubMed Web of Science ®Google Scholar
• Martin DP, Weaver S, Tegally H, et al. The emergence and ongoing convergent evolution of the N501Y lineages coincides with a major global shift in the SARS-CoV-2 selective landscape. medRxiv: the preprint server for health sciences. 2021.
   Google Scholar
• Murray CJL, Piot P. The potential future of the COVID-19 pandemic: will SARS-CoV-2 become a recurrent seasonal infection? JAMA. 2021;325(13):1249–1250. doi:10.1001/jama.2021.2828.
   PubMed Web of Science ®Google Scholar
• Phillips N. The coronavirus is here to stay - Here’s what that means. Nature. 2021;590(7846):382–384. doi:10.1038/d41586-021-00396-2.
   PubMed Web of Science ®Google Scholar
• Iftekhar EN, Priesemann V, Balling R, et al. A look into the future of the COVID-19 pandemic in Europe: an expert consultation. Lancet Reg Health Eur. 2021;8:100185. doi:10.1016/j.lanepe.2021.100185.
   PubMedGoogle Scholar
• Lurie N, Saville M, Hatchett R, et al. Developing Covid-19 vaccines at pandemic speed. N Engl J Med. 2020;382(21):1969–1973. doi:10.1056/NEJMp2005630.
   PubMed Web of Science ®Google Scholar
• Amanat F, Krammer F. SARS-CoV-2 vaccines: status report. Immunity. 2020;52(4):583–589. doi:10.1016/j.immuni.2020.03.007.
   PubMed Web of Science ®Google Scholar
• Dai L, Gao GF. Viral targets for vaccines against COVID-19. Nat Rev Immunol. 2021;21(2):73–82. doi:10.1038/s41577-020-00480-0.
   PubMed Web of Science ®Google Scholar
• Katella K. Comparing the COVID-19 vaccines: how are they different? https://wwwyalemedicineorg/news/covid-19-vaccine-comparison. 2021.
   Google Scholar
• He Q, Mao Q, Zhang J, et al. COVID-19 vaccines: current understanding on immunogenicity, safety, and further considerations. Front Immunol. 2021;12:669339. doi:10.3389/fimmu.2021.669339.
   PubMed Web of Science ®Google Scholar
• Dowdle WR. The principles of disease elimination and eradication. Bull World Health Organ. 1998;76(Suppl 2):22–25.
   PubMedGoogle Scholar
• Abdel-Moneim AS, Abdelwhab EM. Evidence for SARS-CoV-2 infection of animal hosts. Pathogens (Basel, Switzerland). 2020;9(7):529. doi:10.3390/pathogens9070529.
   PubMed Web of Science ®Google Scholar
• Oude Munnink BB, Sikkema RS, Nieuwenhuijse DF, et al. Transmission of SARS-CoV-2 on mink farms between humans and mink and back to humans. Science. 2021;371(6525):172–177. doi:10.1126/science.abe5901.
   PubMed Web of Science ®Google Scholar
• Chen J, Lu H. New challenges to fighting COVID-19: virus variants, potential vaccines, and development of antivirals. Biosci Trends. 2021;15(2):126–128. doi:10.5582/bst.2021.01092.
   PubMed Web of Science ®Google Scholar
• Sanders JM, Monogue ML, Jodlowski TZ, et al. Pharmacologic treatments for coronavirus disease 2019 (COVID-19): a review. JAMA. 2020;323(18):1824–1836. doi:10.1001/jama.2020.6019.
   PubMed Web of Science ®Google Scholar
• Deng Q, Rasool RU, Russell RM, et al. Targeting androgen regulation of TMPRSS2 and ACE2 as a therapeutic strategy to combat COVID-19. iScience. 2021;24(3):102254. doi:10.1016/j.isci.2021.102254.
   PubMed Web of Science ®Google Scholar
• Shang C, Zhuang X, Zhang H, et al. Inhibitors of endosomal acidification suppress SARS-CoV-2 replication and relieve viral pneumonia in hACE2 transgenic mice. Virol J. 2021;18(1):46. doi:10.1186/s12985-021-01515-1.
   PubMed Web of Science ®Google Scholar
• Khateeb J, Li Y, Zhang H. Emerging SARS-CoV-2 variants of concern and potential intervention approaches. Crit Care. 2021;25(1):244. doi:10.1186/s13054-021-03662-x.
   PubMed Web of Science ®Google Scholar
• Wysocki J, Ye M, Hassler L, et al. A novel soluble ACE2 variant with prolonged duration of action neutralizes SARS-CoV-2 infection in human kidney organoids. JASN. 2021;32(4):795–803. doi:10.1681/ASN.2020101537.
   Web of Science ®Google Scholar
• Abbott TR, Dhamdhere G, Liu Y, et al. Development of CRISPR as an antiviral strategy to combat SARS-CoV-2 and influenza. Cell. 2020;181(4):865–876.e12. doi:10.1016/j.cell.2020.04.020.
   PubMed Web of Science ®Google Scholar
• Baum A, Ajithdoss D, Copin R, et al. REGN-COV2 antibodies prevent and treat SARS-CoV-2 infection in rhesus macaques and hamsters. Science. 2020;370(6520):1110–1115. doi:10.1126/science.abe2402.
   PubMed Web of Science ®Google Scholar
• Anna RM, Hasan U, Liina H, et al. Intranasal inhibitor blocks omicron and other variants of SARS-CoV-2. Research Square. 2022. Preprint.
   Google Scholar
• Romano CM, Melo FL. Genomic surveillance of SARS-CoV-2: a race against time. Lancet Reg Health Am. 2021;1:100029. doi:10.1016/j.lana.2021.100029.
   PubMedGoogle Scholar
• Robishaw JD, Alter SM, Solano JJ, et al. Genomic surveillance to combat COVID-19: challenges and opportunities. Lancet Microbe. 2021;2(9):e481–e4. doi:10.1016/S2666-5247(21)00121-X.
   PubMedGoogle Scholar
• Jumper J, Evans R, Pritzel A, et al. Highly accurate protein structure prediction with AlphaFold. Nature. 2021;596(7873):583–589. doi:10.1038/s41586-021-03819-2.
   PubMed Web of Science ®Google Scholar
• Oude Munnink BB, Worp N, Nieuwenhuijse DF, et al. The next phase of SARS-CoV-2 surveillance: real-time molecular epidemiology. Nat Med. 2021;27(9):1518–1524. doi:10.1038/s41591-021-01472-w.
   PubMed Web of Science ®Google Scholar
• Limam A. What is a universal coronavirus vaccine and is it achievable? https://newseucgtncom/news/2021-03-21/What-is-a-universal-coronavirus-vaccine-and-is-it-achievable–YN8cpkETqU/indexhtml. 2021.
   Google Scholar
• Page ML. Covid-resistant people point way to universal coronavirus vaccine. https://wwwnewscientistcom/article/2296980-covid-resistant-people-point-way-to-universal-coronavirus-vaccine/. 2021.
   Google Scholar
• Swadling L, Diniz MO, Schmidt NM, et al. Pre-existing polymerase-specific T cells expand in abortive seronegative SARS-CoV-2. Nature. 2021;601(7891):110–117.
   PubMed Web of Science ®Google Scholar
• CORONADX. Are we able to detect all coronavirus variants? https://coronadx-projecteu/magazine/are-we-able-to-detect-all-coronavirus-variants-2/. 2021.
   Google Scholar
• Aspatwar A, Gong W, Wang S, et al. Tuberculosis vaccine BCG: the magical effect of the old vaccine in the fight against the COVID-19 pandemic bioRxiv. 2021.
   Google Scholar
• Jimenez D. A century-old tuberculosis vaccine could help fight Covid-19 in the elderly. https://wwwpharmaceutical-technologycom/features/tuber­culosis-vaccine-covid-19-elderly/. 2021.
   Google Scholar
• Amirlak L, Haddad R, Hardy JD, et al. Effectiveness of booster BCG vaccination in preventing Covid-19 infection. Hum Vaccines Immunother. 2021;17(11):3913–3915.
   PubMed Web of Science ®Google Scholar
• Sadeghi R, Masoudi MR, Khanjani N. The commitment for fair distribution of COVID-19 vaccine among all countries of the world. Res Nurs Health. 2021;44(2):266–267. doi:10.1002/nur.22112.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Vaccine equity. https://wwwwhoint/campaigns/vaccine-equity. 2021.
   Google Scholar
• Crisis TC. Zoo animals are getting their COVID vaccines, too. https://wwwnprorg/2021/11/13/1055503677/zoo-animals-are-getting-their-covid-vaccines-too. 2021.
   Google Scholar
• Baum A, Fulton BO, Wloga E, et al. Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies. Science. 2020;369(6506):1014–1018. doi:10.1126/science.abd0831.
   PubMed Web of Science ®Google Scholar